With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome ...

The U.S. Food and Drug Administration has extended its review of GSK's blood cancer drug, Blenrep, as a combination treatment, the company said on Wednesday.

GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug conjugate, Blenrep, developed with Pfizer (PFE) and Kyowa Kirin (OTCPK:KYKOF) ...

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.

European regulators on Friday said that the Duchenne muscular dystrophy gene therapy Elevidys should not be approved ...

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and ...

Blenrep combinations are currently under review in 14 countries, including the U.S., with a Prescription Drug User Fee Act (PDUFA) date of 23 July 2025.

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or refractory multiple myeloma who have previously received at least one line of ...

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA, a cell-surface protein that plays an important role in the survival of plasma cells and is expressed on multiple ...